JDM is defined in this packet as a systemic autoimmune inflammatory condition. The known_genes and inheritance_patterns fields are not populated, consistent with an autoimmune rather than Mendelian genetic etiology. Specific immunological mechanisms underlying the inflammatory process in JDM, including autoantibody profiles or interferon pathway involvement, are not documented in this packet's certified structured fields.

Diagnostic criteria and methods are not documented in this packet's certified structured fields.

One FDA-approved therapy for dermatomyositis is documented in this packet. Octagam 10% (Immune Globulin Intravenous [Human]), marketed by Octapharma USA, carries FDA approval for the treatment of dermatomyositis. This approval covers intravenous immunoglobulin (IVIG) delivery for the indication. Additionally, umbilical cord lining stem cells (ULSC), under development by Restem LLC, hold an FDA orphan drug designation for treatment of idiopathic inflammatory myositis, including dermatomyositis and polymyositis. Orphan designation indicates the treatment is under development for a rare disease population and does not constitute regulatory approval for clinical use. No additional approved therapies are documented in this packet's structured fields.

Prognosis and natural history data are not documented in this packet's certified structured fields.

Four clinical trials in JDM and related inflammatory myopathies are documented in this packet, representing active investigation across pharmacologic and cellular therapy approaches. NCT07111065 — 'FAST for DM: Fatty Acid Supplementation Trial for Dermatomyositis,' sponsored by the National Institute of Environmental Health Sciences (NIEHS) — is a Phase 2 trial recruiting as of August 2026 with projected completion in November 2031. NCT07089121 — 'Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders,' sponsored by Cartesian Therapeutics — is a Phase 1 trial recruiting since January 2026 with completion expected December 2028. NCT06154252 — 'RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy,' sponsored by Cabaletta Bio — is a Phase 2 trial recruiting since December 2023 with completion planned for July 2028. NCT00059748 is a natural history and pathogenesis study of autoimmune disorders, currently recruiting. The research landscape for JDM comprises 226 classified publications, with case reports and review articles representing the dominant literature types alongside biomarker and gene therapy research, and with biologic and drug therapy interventions represented across the trial portfolio.